ERBB2 and breast carcinoma: Next, we sought to determine whether the toxicity profile of trastuzumab deruxtecan, the only ADC approved for breast cancer in both high and low HER2 expression settings, differed between these groups, and whether these differences could be attributed to target expression levels.